Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
Triple-negative breast cancer (TNBC) is an aggressive malignancy that requires effective targeted drug therapy. In this study, we employed in silico methods to evaluate the efficacy of seven approved drugs against human ck2 alpha kinase, a significant modulator of TNBC metastasis and invasiveness. M...
Main Authors: | Tagyedeen H Shoaib, Walaa Ibraheem, Mohammed Abdelrahman, Wadah Osman, Asmaa E Sherif, Ahmed Ashour, Sabrin R M Ibrahim, Kholoud F Ghazawi, Samar F Miski, Sara A Almadani, Duaa Fahad ALsiyud, Gamal A Mohamed, Abdulrahim A Alzain |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0289887&type=printable |
Similar Items
-
Genus <i>Acanthella</i>—A Wealthy Treasure: Secondary Metabolites, Synthesis, Biosynthesis, and Bioactivities
by: Sabrin R. M. Ibrahim, et al.
Published: (2023-04-01) -
Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles
by: Abdalrahim M. Ali, et al.
Published: (2023-03-01) -
Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
by: Alaa Edris, et al.
Published: (2023-04-01) -
Integrating computational methods guided the discovery of phytochemicals as potential Pin1 inhibitors for cancer: pharmacophore modeling, molecular docking, MM-GBSA calculations and molecular dynamics studies
by: Abdulrahim A. Alzain, et al.
Published: (2024-01-01) -
Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies
by: Rua M. Mukhtar, et al.
Published: (2023-06-01)